• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    COMPREHENSIVE HEALTHCARE SYSTEMS ANNOUNCES APPOINTMENT OF NEW BOARD MEMBER AND CHIEF EXECUTIVE OFFICER

    1/25/22 8:00:00 AM ET
    $CERN
    $GE
    $MCK
    Managed Health Care
    Health Care
    Consumer Electronics/Appliances
    Technology
    Get the next $CERN alert in real time by email

    CALGARY, AB, Jan. 25, 2022 /CNW/ - Comprehensive Healthcare Systems Inc. (TSXV:CHS) (the "Company" or "CHS"), an industry leader in Healthcare Benefits Administration software and services, is pleased to announce the appointment of Chris Cosgrove as the Company's new President and Chief Executive Officer ("CEO") and to its board of directors effective February 1, 2022.  Mr. Cosgrove has 25 years of management and leadership experience in the healthcare technology industry and will replace CHS founder, Dr. Hassan Mohaideen, who will continue in his role as Chairman of the board of directors (the "Board") and be appointed Chief Medical Officer of the Company.

    "With a proven track record of leading and growing healthcare technology businesses, Chris is uniquely qualified to carry on our mission to streamline the way consumers navigate their healthcare," said Dr. Mohaideen. "He shares our values and vision and will continue to build upon everything that sets CHS apart. It's been an honor founding and building CHS, and I'm looking forward to working with Chris as we scale the company and grow the impact of CHS's NOVUS platform across the care continuum."

    The board of directors believe that the appointment of Mr. Cosgrove is a pivotal step towards building an institutional-grade sales focused commercial organization to ramp up sales and add new clients. A key focus area for the incoming CEO will be to target federal, state, and local governments in providing solutions to rising healthcare costs and to facilitate transparency in costs and administration. CHS's management and the board of directors believe that organic revenue growth, launching new telehealth solutions (such as for the mental health space) and focusing on strategic acquisitions will be key priority areas for CHS during 2022.

    Chris Cosgrove

    Mr. Cosgrove has been a leader and innovator in healthcare IT for over 30 years. Having worked at both Fortune 100 and early-stage companies, he has extensive experience driving company growth, product value and building high performing teams.

    Mr. Cosgrove's most recent role was Market President of Welltok's Provider Business, a leading healthcare consumer engagement company. Mr. Cosgrove and the team focused on growth and product innovation that ultimately positioned Welltok as a leader in the healthcare data analytics and patient engagement space. Prior to Welltok, he also served as EVP/GM of Vitals, a company focused on patient engagement and transparency, where he led the growth and development of new solutions into the Provider Healthcare Market. Prior to Vitals, Mr. Cosgrove held leadership positions at McKesson Provider Technologies (NYSE:MCK), Cerner Corporation (NASDAQ:CERN) and GE Healthcare (NYSE:GE).

    "With what's going on in the world today, it's never been more important to help consumers understand, navigate and manage their healthcare," Cosgrove said.  "I'm honored to be named CHS's CEO as we work to deliver innovation and value for our customers, helping to streamline the management of benefits for consumers, employers and providers. CHS has the ideal combination of compelling cloud-based offerings, with proven client deployments and a great experienced team.  I believe that CHS's core product can be the industry leader. It is flexible, cost effective, efficient and can be sold to a far wider market. The growth and enhancement of the sales capabilities will be my key priority and I'm excited about what we can accomplish, building off tremendous market growth."

    Pursuant to the employment agreement entered into between Mr. Cosgrove and the Company, CHS has granted Mr. Cosgrove options to acquire up to 500,000 common shares in the capital of CHS (each a "Share"), at an exercise price of $0.45 per Share, and vesting schedule of three years. (the "Stock Options").

    About Comprehensive Healthcare Systems Inc.

    Comprehensive Healthcare Systems Inc. is a corporation incorporated under the laws of the Province of Alberta and is the parent company of Comprehensive Healthcare Systems Inc. (Delaware). The Company is a vertically integrated software as a services (SaaS) company focused on digitizing healthcare with Telehealth and Healthcare Benefits Administration solutions, providing reliable and high-volume transaction capable systems. The Company's state of the art HPS Novus Healthcare Welfare and Benefits Administration (HWBA) SaaS platform is used by clients for all aspects of healthcare benefit administration (including insurance companies, hospitals, doctors and labor unions, through various corporation in which the majority shareholder has controlling ownership), providing healthcare administrative software, licensing and maintenance services.

    Forward-Looking Statements

    Forward-Looking Information

    This news release contains certain "forward-looking information" and "forward-looking statements" (collectively referred to as "forward-looking statements"). These forward-looking statements relate to future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates" or "believes", or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information. Forward-looking statements in this news release include, but may not be limited to, statements about the potential growth of the Company's product to become a future leader./

    Forward-looking statements are based on management's assumptions as at the date the forward-looking statements are provided, including assumptions regarding: the Company's management ability to execute its business strategy. Though management believes that its assumptions are reasonable in the circumstances, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to differ materially from all or any of the future results, performance or achievements expressed or implied by forward-looking statements. Risk factors that could cause the Company's actual results, performance, or achievements to differ from the forward-looking statements in this news release include but may not be limited to: the inability of the Company's management to execute its business strategy, adverse or unexpected changes to regulatory regimes related to the medical industry, and general market and economic risks. Accordingly, readers should not place undue reliance on forward-looking statements.

    The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

    Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    SOURCE Comprehensive Healthcare Systems Inc.

    Cision View original content: http://www.newswire.ca/en/releases/archive/January2022/25/c3409.html

    Get the next $CERN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERN
    $GE
    $MCK

    CompanyDatePrice TargetRatingAnalyst
    GE Aerospace
    $GE
    4/9/2025$205.00Neutral → Buy
    Northcoast
    GE Aerospace
    $GE
    2/18/2025$250.00Buy
    Redburn Atlantic
    GE Aerospace
    $GE
    1/7/2025Neutral
    Northcoast
    McKesson Corporation
    $MCK
    12/4/2024$630.00Neutral
    Mizuho
    McKesson Corporation
    $MCK
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    GE Aerospace
    $GE
    10/14/2024$201.00 → $225.00Outperform
    Bernstein
    McKesson Corporation
    $MCK
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    GE Aerospace
    $GE
    9/10/2024$201.00Outperform
    Bernstein
    More analyst ratings

    $CERN
    $GE
    $MCK
    Financials

    Live finance-specific insights

    See more
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on July 1, 2025, to stockholders of record on June 2, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read

      5/1/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC

      Announces fourth quarter and full year fiscal 2025 earnings release date McKesson Corporation (NYSE:MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, for about $850 million. PRISM physicians will retain an approximate 20% interest. The acquisition enables McKesson to develop a leading retinal and ophthalmology platform and expand McKesson's differentiated value proposition, clinical services a

      4/2/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $CERN
    $GE
    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CERN
    $GE
    $MCK
    SEC Filings

    See more

    $CERN
    $GE
    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GE Aerospace upgraded by Northcoast with a new price target

      Northcoast upgraded GE Aerospace from Neutral to Buy and set a new price target of $205.00

      4/9/25 8:08:47 AM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • Redburn Atlantic initiated coverage on GE Aerospace with a new price target

      Redburn Atlantic initiated coverage of GE Aerospace with a rating of Buy and set a new price target of $250.00

      2/18/25 7:08:41 AM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • Northcoast initiated coverage on GE Aerospace

      Northcoast initiated coverage of GE Aerospace with a rating of Neutral

      1/7/25 8:59:24 AM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MCKESSON CORP (0000927653) (Filer)

      5/8/25 4:06:16 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form 13F-HR filed by GE Aerospace

      13F-HR - GENERAL ELECTRIC CO (0000040545) (Filer)

      5/1/25 2:54:10 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • SEC Form DEFA14A filed by GE Aerospace

      DEFA14A - GENERAL ELECTRIC CO (0000040545) (Filer)

      4/22/25 4:10:55 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on July 1, 2025, to stockholders of record on June 2, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read

      5/1/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC

      Announces fourth quarter and full year fiscal 2025 earnings release date McKesson Corporation (NYSE:MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, for about $850 million. PRISM physicians will retain an approximate 20% interest. The acquisition enables McKesson to develop a leading retinal and ophthalmology platform and expand McKesson's differentiated value proposition, clinical services a

      4/2/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $CERN
    $GE
    $MCK
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

      Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

      8/26/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • MultiPlan Announces CFO Transition

      MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, as well as payment and revenue integrity solutions to the U.S. healthcare industry, announced today its CFO transition plan and named Doug Garis as EVP and CFO, effective August 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731993142/en/Doug Garis named EVP and CFO of MultiPlan (Photo: Business Wire) Jim Head, who has served as EVP and CFO of MultiPlan since November 2021, will transition to a Strategic Advisor role to the Company through the end of the

      8/1/24 6:00:00 AM ET
      $DOOR
      $MPLN
      $ORCL
      $CERN
      Forest Products
      Basic Materials
      Business Services
      Consumer Discretionary

    $CERN
    $GE
    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GE Aerospace

      SC 13G/A - GENERAL ELECTRIC CO (0000040545) (Subject)

      11/12/24 12:54:20 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/13/24 5:09:38 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by General Electric Company (Amendment)

      SC 13G/A - GENERAL ELECTRIC CO (0000040545) (Subject)

      2/13/24 4:55:49 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology

    $CERN
    $GE
    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcdew Darren W was granted 968 shares, increasing direct ownership by 83% to 2,133 units (SEC Form 4)

      4 - GENERAL ELECTRIC CO (0000040545) (Issuer)

      5/7/25 4:14:34 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • Director Lesjak Catherine A was granted 968 shares, increasing direct ownership by 83% to 2,133 units (SEC Form 4)

      4 - GENERAL ELECTRIC CO (0000040545) (Issuer)

      5/7/25 4:14:21 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • Director Horton Thomas W was granted 968 shares, increasing direct ownership by 83% to 2,133 units (SEC Form 4)

      4 - GENERAL ELECTRIC CO (0000040545) (Issuer)

      5/7/25 4:14:10 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology